Principal Investigator Western Reserve Academy Hudson, Ohio, United States
Disclosure(s):
Roberto Aguilar, PhD: No financial relationships to disclose
Introduction/Rationale: Bruton’s Tyrosine Kinase (BTK) is a cytoplasmic kinase best known for its role in B-cell receptor signaling, but aberrant activation of related kinase pathways has also been observed in T-cell malignancies. Targeting BTK and associated signaling nodes represents a potential therapeutic approach for T-cell cancers. This study investigates the effects of BTK inhibition on two T-cell models, Jurkat (human T-cell leukemia) and EL4 (mouse T-cell lymphoma), to assess cross-species responses and therapeutic relevance.
Methods: Jurkat and EL4 cells were cultured under standard conditions and treated with a selective BTK inhibitor. Cell proliferation was measured using colorimetric viability assays, and ELISA was used to evaluate phosphorylation of downstream signaling proteins. SDS-PAGE was performed to assess changes in protein expression patterns following inhibitor treatment.
Results: BTK inhibition decreased proliferation in both Jurkat and EL4 cells compared with controls. ELISA data indicated reduced phosphorylation of signaling intermediates associated with cell survival, and SDS-PAGE analysis revealed distinct shifts in protein banding consistent with suppression of kinase-dependent pathways.
Conclusion: These results suggest that BTK-related signaling contributes to proliferation in T-cell leukemia and lymphoma models. Continued experiments will further define the pathways affected by BTK inhibition and evaluate its potential as a therapeutic target in T-cell malignancies.
